Amendment No. 11 to Schedule 13D
The following constitutes Amendment No. 11 (Amendment No. 11) to the Schedule 13D filed with the Securities and Exchange Commission
(SEC) by Ospraie Ag Science LLC and Dwight Anderson on February 12, 2018, as amended by Amendment No. 1 filed on August 12, 2019, Amendment No. 2 filed on September 5, 2019, Amendment No. 3 filed on
December 20, 2019, Amendment No. 4 filed on January 3, 2020, Amendment No. 5 filed on March 6, 2020, Amendment No. 6 filed on April 16, 2020, Amendment No. 7 filed on May 1, 2020, Amendment No. 8
filed on October 13, 2020, Amendment No. 9 filed on December 17, 2020, and Amendment No. 10 filed on March 16, 2021. This Amendment No. 11 amends and supplements the Schedule 13D as specifically set forth herein.
All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D, as amended. Information
given in response to each item shall be deemed incorporated by reference in all other items, as applicable.
ITEM 3.
|
SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
|
Item 3 of the Schedule 13D is supplemented and superseded, as the case may be, as follows:
The disclosure in Item 4 is incorporated herein by reference.
ITEM 4.
|
PURPOSE OF TRANSACTION
|
Item 4 of the Schedule 13D is supplemented and superseded, as the case may be, as follows:
On December 15, 2021, Ospraie LLC exercised the fifth and final tranche of Exchange Agreement Warrants and purchased the 3,553,583 shares of Common Stock
underlying such Exchange Agreement Warrants for $0.75 per share.
The Reporting Persons may engage in discussions with the Issuers management, the
Board, other shareholders of the Issuer and other relevant parties, including representatives of any of the foregoing, concerning the Reporting Persons investment in the Common Stock and the Issuer, including, without limitation, matters
concerning the Issuers business, operations, governance, management, capitalization and strategic plans. The Reporting Persons may exchange information with any persons pursuant to appropriate confidentiality or similar agreements or
otherwise, work together with any persons pursuant to joint agreements or otherwise, propose changes in the Issuers business, operations, governance, management, capitalization or strategic plans, or propose or engage in one or more other
actions set forth under subparagraphs (a)-(j) of Item 4 of Schedule 13D.
The Reporting Persons intend to review their investment in the Issuer on a
continuing basis. Depending on various factors, including, without limitation, the outcome of any discussions referenced above, the Issuers financial position, results and strategic direction, actions taken by the Issuers management or
the Board, price levels of the Common Stock, other investment opportunities available to the Reporting Persons, conditions in the securities market and general economic and industry conditions, the Reporting Persons may in the future take such
actions with respect to their